[Frame — 00:55] Liz Parrish – Introduction.
[Frame — 06:10] Gene therapy & deliver mechanisms — AAV2.
[Frame — 13:55] Gene therapy — myostatin inhibitor.
[Frame — 18:50] Telomerase
Disclaimer: This communication is for information purposes only not an investment recommendation.
Acarbose and Metformin are commonly used to treat type 2 diabetes, but now they are also being tested for anti-aging effects, and according to the researchers these two FDA approved drugs have big promise.
In mice testing Acarbose and Metformin were demonstrated to increase health, lifespan, and longevity of the animals. These two drugs are now being tested in monkeys that have a similar physiology, reproductive system, and aging pattern as humans, in research being conducted at Texas Biomedical Research Institute which is supported by a pilot grant provided by the San Antonio Claude D. Pepper Older Americans Independence Center.
“I think this type of research can change what life is like for geriatric people,” said Corinna Ross, Ph.D, Associate Professor, Southwest National Primate Research Center at Texas BioMed.
Lifespan.io
A new study published in mSystems, a journal from the American Society for Microbiology, shows that the skin and mouth microbiomes are better predictors of age than the gut microbiome.
A very broad study
The authors used a very large population that is highly impressive among studies of this kind. Previously, a team containing some of the same researchers had done a gut microbiome study of over four thousand people from multiple countries [1]. This time, the researchers took skin, saliva, and fecal samples from roughly 2,000, 2,500, and 4,500 people, respectively; this study was done with nearly 9,000 people in total, and the team stated that it was the most comprehensive microbiome study done to date. The team used a “random forest” machine learning approach to determine what microbiota were and were not predictive of age [2].
Wall Street’s Biotech Investment Wizard — On this most recent ideaXme (http://radioideaxme.com/) episode, I was honored to be joined by my friend, and biotech / pharma / healthcare investment banker extraordinaire, Frederick Frank, to talk about his 50-year career history behind the industry’s mega-deals — #Ideaxme #Biopharma #Biotech #WallStreet #Mergers #Acquisitions #VentureCapital #Genentech #Roche #BristolMyersSquibb #PrivateEquity #Health #Wellness #Longevity #Regeneration #LifeExtension #Aging #IraPastor #Bioquark #Regenerage
Ira Pastor, ideaXme exponential health ambassador, interviews Fred Frank, Founder and Chair of Evolution Life Science Partners, an investment bank focused on the needs of life sciences and healthcare companies.
Ira Pastor Comments:
On several recent shows we’ve been discussing some of the novel, alternative funding pools that have been emerging in and around the biotech space, specifically related to some of the unmet medical needs of which we have been focusing on, on the ideaXme show, particularly related to the age-tech and longevity biotech fronts.
We have had guests join us from both the $125 Million Healthy Ageing Challenge program of UKRI (UK Research and Innovation)and the US$30 Million Healthy Longevity Global Grand Challenge of the U.S. National Academy of Medicine. We’ve have also talked to folks at the XPrize Foundation, specifically related to their upcoming inducement prize contest for therapeutics for the diseases of aging.
Lifespan.io
On this informative episode of X10, Giuliano explains proteins and how they misfold, causing the hallmark of aging known as loss of proteostasis- which leads to Alzheimer’s disease and other dangerous diseases.
Is ageing a disease? One that can be ‘cured’? BBC’s Gabriela Torres meets the self-experimenters and scientists who are trying to dramatically extend our lives.
Please subscribe HERE http://bit.ly/1rbfUog
World In Pictures https://www.youtube.com/playlist?list=PLS3XGZxi7cBX37n4R0UGJN-TLiQOm7ZTP
A molecular switch has been identified by scientists at the University of California that controls the immune machinery which is responsible for chronic inflammation within the body; findings published in the journal Cell Metabolism may lead to new ways to halt and/or reverse age related conditions such as cancer, diabetes, Alzheimer’s and Parkinson’s disease.
“My lab is very interested in understanding the reversibility of aging,” said senior author Danica Chen, associate professor of metabolic biology, nutritional sciences and toxicology at UC Berkeley. “In the past, we showed that aged stem cells can be rejuvenated. Now, we are asking: to what extent can aging be reversed? And we are doing that by looking at physiological conditions, like inflammation and insulin resistance, that have been associated with aging-related degeneration and diseases.”
A bulky collection of NLRP3 inflammasome immune proteins which are responsible for sensing potential threats to the body and launching an inflammatory response were shown to be essentially switched off by removing some molecular matter in a deacetylation process. Overactivation of NLRP3 inflammasomes is linked to a range of chronic conditions such as cancer, dementia, diabetes, and multiple sclerosis; this study suggests that drugs targeted towards deacetylation these NLRP3 inflammasomes may help to prevent and/or treat many age related conditions and even possibly age related degeneration itself in general.
Neuroprosthesis is the process of using direct electric stimulation to enable proper functioning of the nervous system. Neuroprosthetic devices supplements the input or the output signals to the neural system, enabling the individual to carry out proper functioning and physical activities. Some of the purposes which involve the use of neuroprosthetics include, techniques for bladder and bowel control, deep brain stimulation, and restoration of mobility and respiration to paralyzed individuals.
Get PDF sample copy of study @ http://bit.ly/39hTnku
Brain disorders exhibits a considerable social and economic burden in Europe. According to WHO survey, brain disorders are responsible for 35% of Europe’s total disease burden. This burden is increasing due to increasing number of aging population in Europe, and requires a considerable attention to address the treatment issues as all the cases does not respond to medication therapy.
Practice teams are urged to share details with clients about this canine longevity study, whose long-term goal is to help pets and people live longer, healthier lives.
Our friends at Foresight Institute and 100 Plus Capital have started regular longevity salons to coordinate the growing longevity enthusiasm and onboard new investors into the space. You are invited to kick off this series with aperitifs and hors d’oeuvre to discuss the current innovations that have been fueling the recent optimism in the field:
Longevity Investment Take-Off: What’s Different This Time, What’s Missing?
As a friend of Lifespan.io, you are welcome to use the code lifespan.io for a 50% discount on the ticket price.
